Physician profile
Mark M Mayes
NPI 1427056571
$756.10
in general payments reported to CMS, 2019-2025
11 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $112 · 2022: $167 · 2023: $134 · 2024: $189 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $477.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $476.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $243.24 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $151.27 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $96.56 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $80.27 | 2024-2025 | Rexulti |
| Exact Sciences Corporation | $50.35 | 2023-2024 | Cologuard Collection Kit |
| Novo Nordisk INC | $30.37 | 2023-2025 | Ozempic |
| Glaxosmithkline, LLC. | $28.61 | 2022-2023 | Shingrix, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $22.50 | 2022 | |
| Neurocrine Biosciences, INC. | $18.64 | 2024 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.75 | 2025 | Caplyta |
| Inspire Medical Systems, INC. | $16.54 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mayes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.